Thematic Take: contents - Pharma Technology Focus | Issue 148 | November 2024

10/07/2024 00:00:00

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturing Go to article: Editor's letter Go to article: Contents Go to article: Mimotopes Company Insight Go to article: Mimotopes Go to article: Syngene Company Insight Go to article: Syngene Go to article: Briefing Go to article: News in Numbers Go to article: Latest News Go to article: Latest Deals Go to article: Project Updates Go to article: PCI Pharma Services Go to article: AlfatestLAB - CPHI Go to article: RHEACELL Company Insight Go to article: In Depth Go to article: Cell and gene therapy approvals drive paradigm change in manufacturing Go to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversy Go to article: How the Covid-19 pandemic will help researchers with the mpox emergency Go to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts Go to article: Clinical research in the UK must build on industry collaboration, says NIHR director Go to article: Keytruda and Opdivo: a decade review Go to article: Alphial - CPHI Go to article: Rephine Go to article: Rephine - CPHI Go to article: Thematic Take: AI Go to article: Thematic Take: contents Go to article: Foreword: Generative AI as a force of creative destruction Go to article: The road to advanced AI capabilities Go to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AI Go to article: The impact of AI on the pharma sector Go to article: Case studies: AI in pharma Go to article: Latest news: AI in pharma Go to article: AI boom set to revolutionise healthcare in Europe Go to article: How NVIDIA grew with the healthcare market instead of pushing into it Go to article: Capturing the genAI boom for drug development Go to article: New AI model boosts early osteoporosis diagnosis for ageing populations Go to article: Impact of AI on metabolic disorder clinical trials Go to article: Resist temptation to rapidly roll out AI – executives must focus on talent and training Go to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021 Go to article: Sponsored Supplements Go to article: BEA Technologies Go to article: Techniconsult Firenze - CPHI Go to article: Science4Tech Go to article: Listings Go to article: Events Go to article: Excellence Awards Go to article: Innovation Rankings Go to article: Buyer's Guides Go to article: Next issue